Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · IEX Real-Time Price · USD
10.41
-0.65 (-5.88%)
May 16, 2022 4:00 PM EDT - Market closed
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 3.64 | 0 | 0 |
| Gross Profit | 3.64 | 0 | 0 |
| Selling, General & Admin | 10.33 | 1.8 | 0.77 |
| Research & Development | 26.24 | 3.04 | 3 |
| Operating Expenses | 36.57 | 4.84 | 3.77 |
| Operating Income | -32.93 | -4.84 | -3.77 |
| Interest Expense / Income | 0 | 0.21 | 0.23 |
| Other Expense / Income | -0.26 | 1.74 | 0 |
| Pretax Income | -32.67 | -6.78 | -4 |
| Net Income | -32.67 | -6.78 | -4 |
| Net Income Common | -32.67 | -6.78 | -4 |
| Shares Outstanding (Basic) | 24 | 1 | 1 |
| Shares Outstanding (Diluted) | 24 | 1 | 1 |
| Shares Change | 2471.20% | 36.71% | - |
| EPS (Basic) | -1.39 | -7.41 | -5.98 |
| EPS (Diluted) | -1.39 | -7.41 | -5.98 |
| Free Cash Flow Per Share | -0.78 | -4.77 | -5.72 |
| Gross Margin | 100.00% | - | - |
| Operating Margin | -905.39% | - | - |
| Profit Margin | -898.32% | - | - |
| Free Cash Flow Margin | -507.51% | - | - |
| EBITDA | -32.56 | -6.57 | -3.77 |
| EBITDA Margin | -895.22% | - | - |
| EBIT | -32.67 | -6.58 | -3.77 |
| EBIT Margin | -898.32% | - | - |
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).